April 03, 2018 - Akers Biosciences Inc. (NASDAQ:AKER) has filed a financial statement reporting Shares Float of $10,201,326 USD. Previously, on March 30, 2016, Akers Biosciences Inc. reported Shares Float of $22,380,041 USD. This represents a change of -54.42% in Shares Float.

Period EndPeriodValue
2017-12-31 2017-A 10,201,326
2015-12-31 2015-A 22,380,041
2014-12-31 2014-A 20,852,006
2016-12-31 2016-A 14,897,365
AdditionalExpensesFromExerciseOfWarrants AllocatedShareBasedCompensationExpense CostOfRevenue DecreaseInPrepaidExpensesRelatedParty DeferredIncomeTaxExpenseBenefit DeferredOtherTaxExpenseBenefit DeferredRevenueRevenueRecognized1 DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther ExpensesRelatedToModificationOfWarrants FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths FiniteLivedIntangibleAssetsAmortizationExpenseYearFive FiniteLivedIntangibleAssetsAmortizationExpenseYearFour FiniteLivedIntangibleAssetsAmortizationExpenseYearThree FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo GeneralAndAdministrativeExpense IncreaseDecreaseInPrepaidExpense LicenseAndServicesRevenue NonoperatingIncomeExpense PrepaidExpenseCurrent PrepaidExpensesRelatedPartyCurrent PrepaidExpensesRelatedPartyNonCurrent ResearchAndDevelopmentExpense ResearchAndDevelopmentExpensesRelatedParty RevenueFromRelatedParties RevenueRecognitionRebatesExpense Revenues RoyaltyExpense SalesAndMarketingExpensesRelatedParty SalesRevenueGoodsGross SalesRevenueGoodsNet SellingAndMarketingExpense StockOptionPlanExpense WarrantModificationExpense

Related News Stories

Your Daily Pharma Scoop: Reata Provides Update, Assembly Biosciences Data, Bellicum's BPX-501

2018-04-13 seekingalpha
Today we will discuss Reata Pharmaceuticals (RETA), which provided an update on the phase 2 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) due to Alport syndrome. (63-14)

Akers Biosciences (AKER) CEO John Gormally on Q4 2017 Results - Earnings Call Transcript

2018-04-03 seekingalpha
Good morning, and welcome to the Akers Biosciences Conference Call to discuss 2017 Earnings. As a reminder, this conference call is being recorded. I would now like to introduce your host for today’s conference, Ben Simons with Akers Corporate Communications team. (3-14)

Your Daily Pharma Scoop: Flex Pharma Data, Protagonist Setback, ImmunoGen Results

2018-03-27 seekingalpha
Flex Pharma (NASDAQ:FLKS) shares moved up sharply in early trading on Monday after the company announced positive top-line data from the phase 2 study of FLKS-787 in multiple sclerosis (NYSE:MS) patients with frequent muscle cramps/spasms and spasticity. (110-1)

CUSIP: 00973E102